|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A polymorphic variant allele (T-allele) in the 3'-UTR of prohibitin (C-to-T at nucleotide 729) was reported to be associated with an increased risk of breast cancer.
|
28294412 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The purpose of the present study was to determine whether protein phosphatase Mg2+/Mn2+ dependent 1D, β-1,3-N-acetylglucosaminyltransferase, neural precursor cell expressed, developmentally down-regulated 9, prohibitin, phosphoinositide-3-kinase regulatory subunit 5 (PIK3R5), phosphatidylinositol-5-phosphate 4-kinase type IIα, TRF1-interacting ankyrin-related ADP-ribose polymerase 2, BCL2 associated agonist of cell death, G2 and S-phase expressed 1 and PAX interacting protein 1 genes, described as prognostic markers in breast cancer in a previous microarray study, are also predictors of lymph node involvement in breast carcinoma Reverse transcription-quantitative polymerase chain reaction analysis was performed on primary breast tumor tissues from women with negative lymph node involvement (n=27) compared with primary tumor tissues from women with positive lymph node involvement (n=23), and was also performed on primary tumors and paired lymph node metastases (n=11).
|
28123587 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We detected that PHB could inhibit breast cancer cell proliferation, change cell cycle distribution and promote cell apoptosis in the ER-positive breast cancer cells.
|
28272969 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Important mechanisms for PHB have been unveiled in several cancers, especially with regard to the androgen independent state of prostate cancer (PC) and oestrogen dependent breast cancer.
|
26450374 |
2015 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In summary, Prohibitin may be associated with breast cancer and its down expression can serve as a potential biomarker for the effective assessment of the disease.
|
23715748 |
2013 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PHB amplification was most common in the ERBB2+ breast cancer subtype, although high expression was most prevalent in basal-like and luminal B cancers.
|
24247619 |
2013 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the sub-group analysis, prohibitin 3' untranslated region C > T gene polymorphism and cancer risk appeared associated with the risk of breast cancer, but not ovarian cancer.
|
22994754 |
2012 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, mitochondrial protein prohibitin has shown to be differentially distributed in mitochondria and in nucleus for normal breast cells and breast cancer cell lines, respectively.
|
21246238 |
2011 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The prohibitin T variant is not associated with the risk of breast cancer in Turkish women.
|
18494604 |
2008 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Prohibitin (PHB) was found to be overexpressed in breast cancer and thus is suggested as a biomarker in that disease.
|
18709484 |
2008 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the PHB 3'UTR T allele increases the risk of breast cancer in patients who are already at increased risk of disease.
|
17004108 |
2007 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings suggest that the prohibitin/Brg1/Brm node is a major cellular target for estrogen antagonists, and thereby also implicate prohibitin/Brg1/Brm as potentially important targets for breast cancer therapy.
|
15141164 |
2004 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Two allelic forms (C versus T) of the prohibitin 3'UTR exist, and carriers of the less common variant (Tallele) with a family history of breast cancer exhibited an increased risk of breast cancer.
|
14500355 |
2003 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Prohibitin 3' untranslated region polymorphism and breast cancer risk in Australian women.
|
12354477 |
2002 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These data suggest that prohibitin genotyping has value in assessing risk of breast cancer in women aged 50 years or younger with at least one first-degree relative with the disease.
|
11377649 |
2001 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
All of the breast cancer cell lines overexpress the longer form of the prohibitin mRNA (1.9 kb) and the protein.
|
8809404 |
1996 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
For many others, such as MYC, CCND1, EMS1, EGF, RB1, NME, DCC and prohibitin, the evidence is still largely circumstantial, or obtained only by in vitro studies on breast cancer cell lines.
|
7819270 |
1994 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In addition, sequence analysis of exon 4 of human prohibitin gene revealed mutations in 4 of 23 sporadic breast carcinomas.
|
8349162 |
1993 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|